Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.

Emerging Company Profile Regular column feature image Version 2

Pionyr Immunotherapeutics Inc.is part of a huge second wave of companies looking to take immuno-oncology to the next level – changing the tumor microenvironment to overcome limitations of the leading available drug classes – but the company hopes that a highly precise approach will help it stand out from the crowd.

Bristol-Myers Squibb Co.and Merck & Co. Inc. have paved the way in immuno-oncology with checkpoint inhibitors that target...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Start-Ups & SMEs

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.